<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/09/2020.04.07.030734.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.07.030734v1"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.07.030734"/>
  <meta name="DC.Date" content="2020-04-09"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="Â© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="Repurposing existing drugs is a timely option to cope with COVID-19. We predicted therapeutic candidates that could reverse the gene expression of coronavirus-infected host cells. Thirteen expression signatures computed from various experimental conditions and preclinical models could be reversed by those compounds known to be effective against SARS- or MERS-CoV, as well as the drug candidates recently shown to be effective against SARS-CoV-2. We selected ten novel candidates to further evaluate their in vitro efficacy against SARS-CoV-2 infection. Four compounds bortezomib, dactolisib, alvocidib and methotrexate inhibited the formation of virus infection-induced cytopathic effect in Vero E6 cells at 1 uM, yet such a concentration seems toxic to the cells as well. While the evaluation in other permissive cells and the prediction of toxicity are needed to optimize and minimize their antiviral activity and cytotoxicity, respectively, this computational approach has the potential to rapidly and rationally identify drug candidates against COVID-19. ### Competing Interest Statement"/>
  <meta name="DC.Contributor" content="Jing Xing"/>
  <meta name="DC.Contributor" content="Rama Shankar"/>
  <meta name="DC.Contributor" content="Aleksandra Drelich"/>
  <meta name="DC.Contributor" content="Shreya Paithankar"/>
  <meta name="DC.Contributor" content="Eugene Chekalin"/>
  <meta name="DC.Contributor" content="Thomas Dexheimer"/>
  <meta name="DC.Contributor" content="Surender Rajasekaran"/>
  <meta name="DC.Contributor" content="Chien-Te Kent Tseng"/>
  <meta name="DC.Contributor" content="Bin Chen"/>
  <meta name="article:published_time" content="2020-04-09"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;Repurposing existing drugs is a timely option to cope with COVID-19. We predicted therapeutic candidates that could reverse the gene expression of coronavirus-infected host cells. Thirteen expression signatures computed from various experimental conditions and preclinical models could be reversed by those compounds known to be effective against SARS- or MERS-CoV, as well as the drug candidates recently shown to be effective against SARS-CoV-2. We selected ten novel candidates to further evaluate their in vitro efficacy against SARS-CoV-2 infection. Four compounds bortezomib, dactolisib, alvocidib and methotrexate inhibited the formation of virus infection-induced cytopathic effect in Vero E6 cells at 1 uM, yet such a concentration seems toxic to the cells as well. While the evaluation in other permissive cells and the prediction of toxicity are needed to optimize and minimize their antiviral activity and cytotoxicity, respectively, this computational approach has the potential to rapidly and rationally identify drug candidates against COVID-19.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.07.030734v1"/>
  <meta name="citation_id" content="2020.04.07.030734v1"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.030734v1"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.030734v1.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.030734v1.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/09/2020.04.07.030734.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.07.030734"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.07.030734"/>
  <meta name="citation_author" content="Jing Xing"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author" content="Rama Shankar"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author" content="Aleksandra Drelich"/>
  <meta name="citation_author_institution" content="University of Texas Medical Branch;"/>
  <meta name="citation_author" content="Shreya Paithankar"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author" content="Eugene Chekalin"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author" content="Thomas Dexheimer"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author" content="Surender Rajasekaran"/>
  <meta name="citation_author_institution" content="Helen Devos Hospital"/>
  <meta name="citation_author" content="Chien-Te Kent Tseng"/>
  <meta name="citation_author_institution" content="University of Texas Medical Branch;"/>
  <meta name="citation_author" content="Bin Chen"/>
  <meta name="citation_author_institution" content="Michigan State University;"/>
  <meta name="citation_author_email" content="chenbi12@msu.edu"/>
  <meta name="twitter:title" content="Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="Repurposing existing drugs is a timely option to cope with COVID-19. We predicted therapeutic candidates that could reverse the gene expression of coronavirus-infected host cells. Thirteen expression signatures computed from various experimental conditions and preclinical models could be reversed by those compounds known to be effective against SARS- or MERS-CoV, as well as the drug candidates recently shown to be effective against SARS-CoV-2. We selected ten novel candidates to further evaluate their in vitro efficacy against SARS-CoV-2 infection. Four compounds bortezomib, dactolisib, alvocidib and methotrexate inhibited the formation of virus infection-induced cytopathic effect in Vero E6 cells at 1 uM, yet such a concentration seems toxic to the cells as well. While the evaluation in other permissive cells and the prediction of toxicity are needed to optimize and minimize their antiviral activity and cytotoxicity, respectively, this computational approach has the potential to rapidly and rationally identify drug candidates against COVID-19. ### Competing Interest Statement"/>
  <meta name="og-title" property="og:title" content="Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.07.030734v1"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="Repurposing existing drugs is a timely option to cope with COVID-19. We predicted therapeutic candidates that could reverse the gene expression of coronavirus-infected host cells. Thirteen expression signatures computed from various experimental conditions and preclinical models could be reversed by those compounds known to be effective against SARS- or MERS-CoV, as well as the drug candidates recently shown to be effective against SARS-CoV-2. We selected ten novel candidates to further evaluate their in vitro efficacy against SARS-CoV-2 infection. Four compounds bortezomib, dactolisib, alvocidib and methotrexate inhibited the formation of virus infection-induced cytopathic effect in Vero E6 cells at 1 uM, yet such a concentration seems toxic to the cells as well. While the evaluation in other permissive cells and the prediction of toxicity are needed to optimize and minimize their antiviral activity and cytotoxicity, respectively, this computational approach has the potential to rapidly and rationally identify drug candidates against COVID-19. ### Competing Interest Statement"/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-09"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19 | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1237285 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">Repurposing existing drugs is a timely option to cope with COVID-19. We predicted therapeutic candidates that could reverse the gene expression of coronavirus-infected host cells. Thirteen expression signatures computed from various experimental conditions and preclinical models could be reversed by those compounds known to be effective against SARS- or MERS-CoV, as well as the drug candidates recently shown to be effective against SARS-CoV-2. We selected ten novel candidates to further evaluate their in vitro efficacy against SARS-CoV-2 infection. Four compounds bortezomib, dactolisib, alvocidib and methotrexate inhibited the formation of virus infection-induced cytopathic effect in Vero E6 cells at 1 uM, yet such a concentration seems toxic to the cells as well. While the evaluation in other permissive cells and the prediction of toxicity are needed to optimize and minimize their antiviral activity and cytotoxicity, respectively, this computational approach has the potential to rapidly and rationally identify drug candidates against COVID-19.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3"/>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
